{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:58:49Z","timestamp":1785214729886,"version":"3.55.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Dupilumab, an IL-4 and IL-13 inhibitor, has been approved for the treatment of eosinophilic esophagitis (EoE), a type two inflammatory disease. Few studies from Saudi Arabia have reported the prevalence and characteristics of EoE and treatment response, particularly dupilumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To report dupilumab treatment outcomes in adult Saudi patients with EoE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective cohort study included all adult treatment-refractory EoE patients who received subcutaneous dupilumab 300 mg between January 2023 and November 2024 at a tertiary hospital in Riyadh, Saudi Arabia. Patient demographics, clinical characteristics, and procedural data were recorded. The primary outcome was to evaluate clinical response to dupilumab, and the secondary outcome was to compare Endoscopic Reference Score (EREFS) and histological outcome following dupilumab treatment with baseline assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 22 patients were included (mean age: 29.7 \u00b1 11.2 years; male: 63.6%). At baseline, most had dysphagia to solids (95.5%) and type 2 inflammatory comorbidities (72.7%). In addition, all patients were on PPIs and had &gt;15 eosinophils\/hpf on histology. After dupilumab treatment, 91% (95% CI: 74.3%\u201397.9%) achieved symptomatic improvement. Post-dupilumab esophagogastroduodenoscopies were performed in 21 patients (median duration: 9.5 months), and most showed reduced inflammatory features. EREFS scores decline from a median of 3 units at baseline to 1 unit after dupilumab treatment (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). Histological remission (&lt;15 eosinophils\/hpf) was achieved in 87.5% of biopsied patients (63% of total cohort). Adverse events occurred in 27.3%, mainly injection-site reactions (66.7%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this cohort study of Saudi adults with refractory eosinophilic esophagitis, dupilumab treatment was associated with significant clinical, endoscopic, and histological improvements, in addition to having an acceptable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjmms.sjmms_43_26","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:00:09Z","timestamp":1784664009000},"page":"254-260","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Dupilumab Treatment in Refractory Eosinophilic Esophagitis: A Retrospective Cohort Study from Saudi Arabia"],"prefix":"10.4103","volume":"14","author":[{"given":"Asma","family":"Alnajjar","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Gastroenterology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muath","family":"Najmi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Gastroenterology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rand","family":"Arnaout","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Allergy and Immunology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alqaraawi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Gastroenterology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alsohaibani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Gastroenterology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymen","family":"Almuhaidb","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Gastroenterology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Alfadda","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Gastroenterology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology, and Scientific Computing, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader","family":"Alajlan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Gastroenterology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"R1-20260728","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/ng.3033","article-title":"Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease","volume":"46","author":"Kottyan","year":"2014","journal-title":"Nat Genet"},{"key":"R2-20260728","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1056\/NEJMra1502863","article-title":"Eosinophilic esophagitis","volume":"373","author":"Furuta","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-20260728","doi-asserted-by":"crossref","first-page":"e13973","DOI":"10.1111\/pai.13973","article-title":"Dupilumab treatment of eosinophilic gastrointestinal disease in an adolescent","volume":"34","author":"Mori","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"R4-20260728","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1398-9995.2012.02787.x","article-title":"Pediatric and adult eosinophilic esophagitis: Similarities and differences","volume":"67","author":"Straumann","year":"2012","journal-title":"Allergy"},{"key":"R5-20260728","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1053\/j.gastro.2008.02.016","article-title":"Eosinophilic esophagitis: A prevalent disease in the United States that affects all age groups","volume":"134","author":"Kapel","year":"2008","journal-title":"Gastroenterology"},{"key":"R6-20260728","doi-asserted-by":"crossref","first-page":"668","DOI":"10.15537\/smj.2018.7.22425","article-title":"Trend, clinical presentations and diagnosis of eosinophilic esophagitis in Saudi children","volume":"39","author":"Saeed","year":"2018","journal-title":"Saudi Med J"},{"key":"R7-20260728","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/1319-3767.77242","article-title":"Eosinophilic esophagitis in Saudi children: Symptoms, histology and endoscopy results","volume":"17","author":"Hasosah","year":"2011","journal-title":"Saudi J Gastroenterol"},{"key":"R8-20260728","first-page":"328253","article-title":"Eosinophilic esophagitis in children from Western Saudi Arabia: Relative frequency, clinical, pathological, endoscopic, and immunological study","author":"Saadah","year":"2012","journal-title":"Gastroenterol Res Pract 2012"},{"key":"R9-20260728","first-page":"526037","article-title":"Eosinophilic esophagitis in a developing country: Is it different from developed countries?","author":"Al-Hussaini","year":"2013","journal-title":"Gastroenterol Res Pract 2013"},{"key":"R10-20260728","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/mi.2013.90","article-title":"Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis","volume":"7","author":"Sherrill","year":"2014","journal-title":"Mucosal Immunol"},{"key":"R11-20260728","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.4049\/jimmunol.168.5.2464","article-title":"IL-5 promotes eosinophil trafficking to the esophagus","volume":"168","author":"Mishra","year":"2002","journal-title":"J Immunol"},{"key":"R12-20260728","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1053\/j.gastro.2009.07.007","article-title":"Biology and treatment of eosinophilic esophagitis","volume":"137","author":"Rothenberg","year":"2009","journal-title":"Gastroenterology"},{"key":"R13-20260728","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3390\/jcm12062259","article-title":"Eosinophilic esophagitis \u2013 What Do We Know So Far?","volume":"6","author":"W\u0105sik","year":"2023","journal-title":"JCM"},{"key":"R14-20260728","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4049\/jimmunol.1000471","article-title":"IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway","volume":"185","author":"Zuo","year":"2010","journal-title":"J Immunol"},{"key":"R15-20260728","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.gastro.2017.06.067","article-title":"Epidemiology and natural history of eosinophilic esophagitis","volume":"154","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"R16-20260728","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.gtc.2014.02.015","article-title":"Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis","volume":"43","author":"Hirano","year":"2014","journal-title":"Gastroenterol Clin North Am"},{"key":"R17-20260728","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"R18-20260728","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.anai.2022.12.014","article-title":"Clinical guidance for the use of dupilumab in eosinophilic esophagitis: A yardstick","volume":"130","author":"Aceves","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R19-20260728","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.cgh.2023.08.015","article-title":"Real-world efficacy of dupilumab in severe, treatment-refractory, and fibrostenotic patients with eosinophilic esophagitis","volume":"22","author":"Lee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R20-20260728","doi-asserted-by":"crossref","first-page":"663","DOI":"10.14309\/ajg.0000000000003087","article-title":"Real-world effectiveness and use of dupilumab in eosinophilic esophagitis","volume":"120","author":"Russin","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"R21-20260728","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5414\/ALX02485E","article-title":"Rapid response to dupilumab in an adult patient with eosinophilic esophagitis and allergic asthma","volume":"8","author":"Klein","year":"2024","journal-title":"Allergol Select"},{"key":"R22-20260728","doi-asserted-by":"crossref","first-page":"e00646","DOI":"10.14309\/ctg.0000000000000646","article-title":"Dupilumab can induce remission of eosinophilic gastritis and duodenitis: A retrospective case series","volume":"15","author":"Sia","year":"2024","journal-title":"Clin Transl Gastroenterol"}],"container-title":["Saudi Journal of Medicine &amp; Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/sjmms.sjmms_43_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:01:46Z","timestamp":1785211306000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.4103\/sjmms.sjmms_43_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/sjmms.sjmms_43_26","relation":{},"ISSN":["1658-631X"],"issn-type":[{"value":"1658-631X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2025-11-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}